EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)
Mostafa, H., Elsheikh, S., Mehanna, R., Omar, E. (2024). EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY). EKB Journal Management System, 49(1), 17-21. doi: 10.21608/adjalexu.2023.198402.1357
Heba Allah Mohamed Mostafa; Sahar Mohamed Elsheikh; Radwa Ali Mehanna; Enas Magdi Omar. "EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)". EKB Journal Management System, 49, 1, 2024, 17-21. doi: 10.21608/adjalexu.2023.198402.1357
Mostafa, H., Elsheikh, S., Mehanna, R., Omar, E. (2024). 'EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)', EKB Journal Management System, 49(1), pp. 17-21. doi: 10.21608/adjalexu.2023.198402.1357
Mostafa, H., Elsheikh, S., Mehanna, R., Omar, E. EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY). EKB Journal Management System, 2024; 49(1): 17-21. doi: 10.21608/adjalexu.2023.198402.1357

EVALUATION OF THE ANTICARCINOGENIC EFFECT OF TAK-242, A TLR4 INHIBITOR, IN ORAL SQUAMOUS CELL CARCINOMA (IN VITRO STUDY)

Alexandria Dental Journal
Article 3, Volume 49, Issue 1, April 2024, Page 17-21  XML PDF (635.66 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2023.198402.1357
View on SCiNiTO View on SCiNiTO
Authors
Heba Allah Mohamed Mostafa email 1; Sahar Mohamed Elsheikh2; Radwa Ali Mehanna3; Enas Magdi Omar4
1Oral pathology department, Faculty of dentistry, Alexandria University, Alexandria, Egypt
2Oral Pathology department, faculty of dentistry, Alexandria university,Egypt.
3Department of Medical Physiology, Faculty of Medicine, Alexandria University, Egypt
4Oral Pathology department, faculty of dentistry, Alexandria university,Alexandria, Egypt.
Abstract
Introduction: Cancer immunotherapy has been recently presented as one of the most efficient treatment approaches for many types of cancer. Toll-like receptor 4 (TLR4) upregulation is involved in the proliferation, migration, and metastasis of many tumors. TAK-242 (also known as Resatorvid) is a TLR4 antagonist which specifically binds to the intracellular domain of the receptor and inhibits all TLR4 interplays with its downstream signaling molecules suggesting a new promising anticarcinogenic strategy.
Objectives: The present research aimed to estimate the antitumorigenic effects of TAK-242 on oral squamous cell carcinoma-4 (OSCC-4) cell line.
Methodology: Verification of TLR4 expression in OSCC-4 cells was established using immunocytochemistry to proof the presence of the studied receptor in the cell line. Next, the cytotoxic effect of TAK-242 was evaluated using MTT assay. The sublethal IC50 dose was calculated then apoptotic induction ability of the drug was assessed using Annexin V/PI assay.
Results: In the present research, it was concluded that TLR4 was significantly expressed in OSCC-4 cells. In addition, its inhibitor (TAK-242) halted cell proliferation by inducing apoptosis of OSCC-4 cells.
Conclusions: TAK-242 has a significant anticarcinogenic effect on OSCC-4 cells and could be further studied experimentally.
Keywords
Innate immunity; TLR4; Oral squamous cell carcinoma; TAK-242
Statistics
Article View: 145
PDF Download: 171